Who
Matthew B. Klein
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, PTC Therapeutics; Director, ClearPoint Neuro.
In numbers
- Trades disclosed
- 102
- Buys
- 0
- Sells
- 34
- Bought
- $0
- Sold
- $12.2M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 16 Apr 2020
- Last trade
- 4 Aug 2026
- Last filed
- 6 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Aug 2026filed 6 Aug 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $706K10,292 at $68.57 | filing |
| 4 Aug 2026filed 6 Aug 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $706K10,292 at $68.57 | filing |
| 21 May 2026filed 26 May 2026 | CLPT ClearPoint NeuroMedical Devices | SEC FORM 4 Sold | $185K16,000 at $11.59 | filing |
| 21 May 2026filed 26 May 2026 | CLPT ClearPoint Neurooption or derivative · Medical Devices | SEC FORM 4 Code A | —12,820 at $0.00 | filing |
| 21 May 2026filed 26 May 2026 | CLPT ClearPoint Neurooption or derivative · Medical Devices | SEC FORM 4 Code A | —12,820 at $0.00 | filing |
| 21 May 2026filed 26 May 2026 | CLPT ClearPoint NeuroMedical Devices | SEC FORM 4 Sold | $185K16,000 at $11.59 | filing |
| 19 May 2026filed 21 May 2026 | CLPT ClearPoint NeuroMedical Devices | SEC FORM 4 Code M | —12,417 | filing |
| 19 May 2026filed 21 May 2026 | CLPT ClearPoint Neurooption or derivative · Medical Devices | SEC FORM 4 Code M | —12,417 | filing |
| 19 May 2026filed 21 May 2026 | CLPT ClearPoint Neurooption or derivative · Medical Devices | SEC FORM 4 Code M | —12,417 | filing |
| 19 May 2026filed 21 May 2026 | CLPT ClearPoint NeuroMedical Devices | SEC FORM 4 Code M | —12,417 | filing |
| 14 May 2026filed 15 May 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $50K679 at $73.06 | filing |
| 14 May 2026filed 15 May 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $528K7,221 at $73.08 | filing |
| 14 May 2026filed 15 May 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $153K2,100 at $73.08 | filing |
| 14 May 2026filed 15 May 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $186K2,572 at $72.46 | filing |
| 14 May 2026filed 15 May 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $50K679 at $73.06 | filing |
| 14 May 2026filed 15 May 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $528K7,221 at $73.08 | filing |
| 14 May 2026filed 15 May 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $153K2,100 at $73.08 | filing |
| 14 May 2026filed 15 May 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $186K2,572 at $72.46 | filing |
| 13 May 2026filed 15 May 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 13 May 2026filed 15 May 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
News
PTC Therapeutics (NASDAQ:PTCT) Director Michael Schmertzler Sells 2,500 Shares of Company StockPTCT · tickerreport.com · 16 Oct 2026ClearPoint Neuro to Announce Third Quarter 2026 Results October 28, ...CLPT · pr-inside.com · 14 Oct 2026PTC Therapeutics (NASDAQ:PTCT) Stock: Insider Mark Elliott Boulding Sells 1,638 SharesPTCT · themarketsdaily.com · 9 Oct 2026Insider Selling: PTC Therapeutics (NASDAQ:PTCT) VP Sells $27,909.60 in StockPTCT · dailypolitical.com · 8 Oct 2026
0 headlines in the last 90 days name Matthew B. Klein; 4 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.